Clinical Trial Update: A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for NeuroVax, a novel TCR peptide vaccine for secondary progressive multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• NeuroVax

Snippet

Sponsor: Immune Response BioPharma, Inc. | Conditions: Multiple Sclerosis | Phase 2 | Status: UNKNOWN